Epizyme provides update regarding tazemetostat clinical program
Epizyme announced that U.S.-based enrollment of new patients into tazemetostat clinical trials is temporarily on hold. Following a safety report of a pediatric patient who developed a secondary lymphoma, the U.S. FDA issued a partial clinical hold affecting new enrollment of patients. April 23, 2018